No Prescription |
 |
 | ||
|
Ismo Retard Imdur |
|
| ||
No Prescription » Prescription Drugs 9 » Ismo Retard Imdur This medication is a nitrate drug. It is used to prevent chest pain (angina) and reduce strain on the heart in patients with heart disease (coronary artery disease). Isosorbide mononitrate relaxes and widens blood vessels so blood can flow more easily.This medication will not relieve chest pain once it occurs. It is also not intended to be taken just before certain activities (e.g. exercise sexual intercourse) to prevent chest pain. Buy Ismo Retard Imdur and other Prescription Drugs 9 products online at Medstore. Buy Online at Medstore - Click Here!
About Ismo Retard Imdur: Product Type: Prescription Drugs 9 Ismo Retard (Imdur Generic Isosorbide Mononitrate) Ismo Retard (Imdur Generic Isosorbide Mononitrate) Imdur Generic Isosorbide Mononitrate 40mg 84 Tablets 2 x 84 Tablets 4 x 84 Tablets Imdur Generic Isosorbide Mononitrate Ismo Retard
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
